Calidi Biotherapeutics, Inc. (CLDI) Financial Ratios
5 years of historical data (2020–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
0.06
↓-99% vs avg
5yr avg: 4.66
30Y Low4.7·High4.7
ROE
-1125.2%
+0% vs avg
5yr avg: -1125.2%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
CLDI Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Calidi Biotherapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Market Cap | $304020 | $9M | $25M | $86M | $281M | — |
| Enterprise Value | $-2250980 | $7M | $31M | $92M | $284M | — |
| P/E Ratio → | -0.00 | — | — | — | 83.14 | — |
| P/S Ratio | — | — | — | 1914.43 | 625.63 | — |
| P/B Ratio | 0.06 | 4.66 | — | — | — | — |
| P/FCF | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
CLDI EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | 2039.23 | 632.41 | — |
| EV / EBITDA | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — |
CLDI Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -1125.2% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | -508.9% | 79.1% | — |
| Operating Margin | — | — | — | -51395.6% | -2334.5% | — |
| Net Profit Margin | — | — | — | -56504.4% | -2435.0% | — |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| ROE | -1125.2% | -1125.2% | — | — | — | — |
| ROA | -183.0% | -183.0% | -463.2% | -849.3% | -417.1% | -428.6% |
| ROIC | — | — | — | — | — | — |
| ROCE | -973.7% | -973.7% | — | — | — | — |
CLDI Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $10M exceeds total debt of $7M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Debt / Equity | 3.58 | 3.58 | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.30 | — | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — |
| Interest Coverage | -23.34 | -23.34 | -7.73 | -146.38 | -17.07 | -41.55 |
Net cash position: cash ($10M) exceeds total debt ($7M)
CLDI Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.08x means Calidi Biotherapeutics, Inc. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has improved from 0.02x to 1.08x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Current Ratio | 1.08 | 1.08 | 0.42 | 0.02 | 0.11 | 0.06 |
| Quick Ratio | 1.08 | 1.08 | 0.42 | 0.02 | 0.11 | 0.06 |
| Cash Ratio | 1.01 | 1.01 | 0.20 | 0.01 | 0.08 | 0.05 |
| Asset Turnover | — | — | — | 0.02 | 0.13 | — |
| Inventory Turnover | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — |
CLDI Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Calidi Biotherapeutics, Inc. returns 100.0% to shareholders annually primarily through dividends.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Dividend Yield | 100.0% | 18.2% | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | 1.2% | — |
| FCF Yield | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Total Shareholder Yield | 100.0% | 18.2% | 0.0% | 0.0% | 0.0% | — |
| Shares Outstanding | — | $664415 | $140162 | $70591 | $238625 | $3M |
Peer Comparison
Compare CLDI with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 CLDIYou | $304020 | -0.0 | — | — | — | — | -1125.2% | — | — |
 IMVT | $7B | -12.8 | — | — | — | — | -64.8% | — | — |
 TGTX | $8B | 19.2 | 67.4 | — | 83.7% | 20.0% | 102.8% | 16.4% | 2.1 |
 ONCY | $108M | -3.3 | — | — | — | — | -10245.9% | — | — |
 CGEN | $190M | 5.3 | 3.2 | 6.1 | 87.3% | 43.1% | 44.8% | 85.9% | 0.1 |
 VVOS | $3M | -0.2 | — | — | 60.4% | -114.1% | -663.0% | -227.3% | — |
 NKTR | $1B | -6.3 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 FATE | $244M | -1.8 | — | — | -94.1% | -2222.4% | -51.8% | -36.5% | — |
 CRSP | $5B | -8.4 | — | — | -6537.0% | -16191.4% | -30.2% | -22.3% | — |
 BEAM | $4B | -42.1 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 NTLA | $2B | -4.1 | — | — | 76.5% | -651.7% | -53.5% | -44.0% | — |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 5 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
CLDI — Frequently Asked Questions
Quick answers to the most common questions about buying CLDI stock.
What is Calidi Biotherapeutics, Inc.'s P/E ratio?
Calidi Biotherapeutics, Inc.'s current P/E ratio is -0.0x. The historical average is 83.1x.
What is Calidi Biotherapeutics, Inc.'s ROE?
Calidi Biotherapeutics, Inc.'s return on equity (ROE) is -1125.2%.
Is CLDI stock overvalued?
Based on historical data, Calidi Biotherapeutics, Inc. is trading at a P/E of -0.0x. Compare with industry peers and growth rates for a complete picture.
What is Calidi Biotherapeutics, Inc.'s dividend yield?
Calidi Biotherapeutics, Inc.'s current dividend yield is 100.00%.